Bruker Corporation (BRKR) | The Buildout — AI Infrastructure
The Verdict
Bruker develops and manufactures high-performance scientific instruments and analytical and diagnostic solutions used to explore life and materials at microscopic, molecular, and cellular levels. In the AI infrastructure buildout, its semiconductor metrology tools inspect and measure chips for advanced packaging and high-bandwidth memory, while its software and lab-digitization business brings AI-ready data to life-science labs.
| Market Cap | — |
| Revenue (TTM) | $3.5B |
| Revenue Growth | +0.4% |
| EBITDA Margin (TTM) | 12.5% |
| Net Debt | $1.5B |
| Earnings Beats | 4 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Semiconductor metrology is a >$300M annual revenue business with about a 30% EBIT margin; H1 orders grew >30% and Q2 orders >50%.
- BSI book-to-bill above 1.0 for four consecutive quarters; Q2 BSI organic bookings grew 10%.
- Cost-savings program raised to north of $140M annualized, with about $30M delivered in Q2 and an additional $20M expected in FY27.
- BEST received about $600M of multi-year superconductor orders from major MRI OEMs plus roughly $80M of fusion research instrument orders; H1 energy research orders grew >100%.
- Biopharma Q2 organic bookings grew >20%, and EU and China academic orders grew >10% and >20% respectively, though U.S. academic demand remains weak.
What We’re Watching
- Back-half-loaded year: H1 organic revenue was -0.8% and Q3 is guided roughly flat to up slightly, so the full-year 1–2% organic guide depends heavily on Q4 execution.
- Customer-controlled deep-tech timing: $20M of semiconductor revenue shifted from Q3 to Q4; an earlier ~$40M pushout was only partially recaptured.
- U.S. academic/government Q2 revenue fell more than $15M year over year, and U.S. academic orders remain weak.
- Automation and spatial biology losses drove a $135M goodwill impairment; Bruker Nano's Q1 segment operating margin was -8.9%.
The thesis is strengthening on orders and cost-out, but the revenue recovery is early and execution-dependent. Q2 returned to organic growth and bookings remain above 1.0, yet first-half organic revenue was still negative and Q2 margin quality included a tariff-refund benefit and a goodwill impairment. The key open question is whether Q4 revenue around $1B converts as guided, including the ultra-high-field NMR delivery.
Earnings Beat
Q2 2026 revenue was $838.5M, up 5.2% reported and 2.8% organic. Non-GAAP gross margin reached 52.1%, up 350 bps year over year. Semiconductor tool orders grew >50%, and BSI book-to-bill was above 1.0 for the fourth consecutive quarter. GAAP diluted EPS was -$0.41 after a $135M non-cash goodwill impairment.
| Metric | Q1 FY2026 | Q4 FY2025 | Q1 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $823M | $977M | $801M | +2.7% |
| Gross margin | 47.3% | 46.0% | 48.8% | -150bps |
| EBITDA | $103M | $170M | $82M | +25.7% |
| EPS | $0.09 | $0.17 | $0.11 | −17.7% |
| BSI book-to-bill | Above 1.0 | Above 1.0 | n/a | — |
The orders are remarkable for the first half and even more so in Q2. Of course, there will be some fluctuations. But if anything, it seems to be accelerating.. We think the visibility of the sector for the next 6 quarters plus seems excellent.— Frank Laukien, August 4, 2026
Management tone: Management shifted from defensive to cautiously confident on orders and costs. They directly quantified the Q2 tariff-refund benefit, explained the Q3-to-Q4 semiconductor shift, and disclosed the goodwill impairment, but declined to give an exact Q4 backlog coverage figure and declined to quantify 2027 revenue growth.
Management Guidance
FY26 reported revenue was trimmed to $3.54B–$3.57B on a lower FX tailwind of 0.5%; organic growth held at 1%–2%, M&A at 1.5%, non-GAAP operating margin expansion at 250–300 bps, and non-GAAP EPS at $2.10–$2.15. Q3 organic revenue is guided roughly flat to up slightly with a slight sequential margin and EPS decline; Q4 is guided for meaningful sequential and year-over-year increases with revenue around $1B.
Trajectory
Revenue returned to organic growth in Q2 at +2.8%, after -4.4% in Q1 and -0.8% for H1. Non-GAAP gross margin reached 52.1%, up 350 bps, and non-GAAP operating margin reached 14.1%, up 510 bps, but about 200 bps came from U.S. tariff refunds. GAAP results included a $135M goodwill impairment. Orders are strengthening, but revenue conversion lags orders by 9–24 months in deep tech.
The Model
The model projects FY+1 revenue of $3,600M and EBITDA of $781M, a 21.7% margin, and FY+2 revenue of $3,820M and EBITDA of $898M, a 23.5% margin. The near-term projection is anchored by management's FY26 reported revenue guide of $3.54B–$3.57B, cost savings of more than $140M, and deep-tech order momentum; FY+2 assumes continued conversion of semiconductor, energy, and superconductor orders plus the additional $20M FY27 structural savings.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $3.4B | $3.6B | $3.8B |
| YoY Growth | — | +4.8% | +6.1% |
| EBITDA | $411M | $781M | $898M |
| EBITDA Margin | 12.0% | 21.7% | 23.5% |
Projections are the median of 5 independent model runs. The model’s revenue sits 2.1% above analyst consensus.
FY26 reported revenue was trimmed to $3.54B–$3.57B on a lower FX tailwind of 0.5%; organic growth held at 1%–2%, M&A at 1.5%, non-GAAP operating margin expansion at 250–300 bps, and non-GAAP EPS at $2.10–$2.15. Q3 organic revenue is guided roughly flat to up slightly with a slight sequential margin and EPS decline; Q4 is guided for meaningful sequential and year-over-year increases with revenue around $1B.
What Could Go Right — and Wrong
- Semiconductor metrology orders convert without further pushouts, sustaining a >$300M annual revenue business at about 30% EBIT margin into FY+2.
- Q4 ultra-high-field NMR installs successfully, supporting the full-year organic growth guide.
- U.S. academic/government orders inflect, closing the demand bifurcation and supporting 2027 revenue.
- Bruker Nano's automation and spatial biology losses narrow, making the margin path cleaner.
- BEST superconductor order flow proves more incremental than renewal and extends revenue through 2029.
- Customer-controlled semiconductor timing slips again, shifting revenue beyond Q4 and pressuring the full-year organic guide.
- U.S. academic/government orders stay weak into 2027, leaving deep tech to carry growth.
- Automation and spatial biology losses persist, limiting operating margin recovery.
- Q4 ultra-high-field NMR installation misses, undermining the roughly $1B Q4 revenue bridge.
- Tariff refunds and FX benefits reverse, exposing lower core operating margin expansion.
Looking Ahead
The next twelve months hinge on Q4 2026 execution and order conversion. Management expects Q3 organic revenue roughly flat to up slightly, then a Q4 step-up with an ultra-high-field NMR delivery. The Q3 report in early November 2026 will be the first under the new four-group structure. Product cycles such as AVANCE NEO-X, MyGenius PRO with Hitachi, and timsMRMS, plus the MIMETAS and Atinary integrations, provide additional milestones.
- Early November 2026Q3 2026 results — Tests flat-to-up Q3 organic revenue and clean margin reset after tariff benefit.
- Q4 2026Q4 revenue target — Tests backlog conversion and the full-year organic growth guide.
- Q4 2026Ultra-high-field NMR delivery — Installation success not guaranteed; historical success rate above 80%.
- 2027New group structure savings — Tests the disclosed FY27 cost-reduction target from the four-group structure.
- 2027Semi order conversion — Tests whether >30% H1 2026 order growth converts to revenue without further slips.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $3.4B | $3.4B | $3.5B | +2.1% |
| Gross Margin | 48.9% | 46.0% | 45.6% | 297bps |
| EBITDA | $437M | $411M | $4.1B | -6.0% |
| EBITDA Margin | 13.0% | 12.0% | 12.5% | 102bps |
| Net Income | $113M | −$9M | −$12M | -107.6% |
| Free Cash Flow | $136M | $43M | $1.6B | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)45.6%
- EBITDA Margin (TTM)12.5%
- Net Margin (TTM)-0.3%
- ROIC4.0%
- FCF Conversion11.9%
- SBC / Revenue0.0%
The Company
Bruker develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions across magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, molecular spectroscopy, and superconducting materials. The AI buildout touches the company directly through Bruker Nano's semiconductor metrology business — a >$300M annual revenue business at about 30% EBIT margin — and smaller AI-relevant pieces such as SciY (~$50M) and ASML EUV supply-chain tools (>$25M).
The company operates manufacturing sites in Germany, Switzerland, the U.S., Malaysia, Israel, and Austria. Effective July 1, 2026, it moved from four legacy reportable segments to four groups: Bruker Biosystems Group, Bruker Nano, BMID, and BEST. Its 10-K discloses dependence on limited-source and single-source suppliers for ceramics, CCD area detectors, X-ray tubes, robotics, infrared optics, detectors, and power supplies, and it has installed helium liquefaction at heavy-use sites to capture and reliquefy roughly 80–90% of helium.
Business Segments
Supply Chain
Bruker sits between component and commodity suppliers and chip, life-science, and energy customers. No neighbor in the provided transcript set mentioned Bruker by name; the semiconductor read-through is indirect.
More on BRKR: Earnings recap